Bundesverband pharmazeutischer Cannabinoidunternehmen

Name

Bundesverband pharmazeutischer Cannabinoidunternehmen

Legal name

Bundesverband pharmazeutischer Cannabinoidunternehmen e. V. (BPC)

Website

https://bpc-deutschland.de

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Berlin

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Marketing or Sales, Operations, Others

Revenue model

1. Membership Fees: BPC generates revenue through membership fees from pharmaceutical cannabinoid companies operating in Germany. Member companies include cannabis producers, importers, and pharmaceutical distributors.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

Bundesverband pharmazeutischer Cannabinoidunternehmen (BPC) is a German non-profit industry association (eingetragener Verein/e.V.) representing approximately 30 pharmaceutical cannabinoid companies operating in Germany. It provides regulatory advocacy, policy representation, educational programming, and member services to advance favourable frameworks for medical cannabis supply and patient access.

Product overview

The Bundesverband pharmazeutischer Cannabinoidunternehmen (BPC) is an industry association, not a product company. It does not offer a unified product platform. Instead, it provides a portfolio of services to its approximately 30 member companies, including educational webinars (Fortbildungs-Webinare), annual professional symposiums (Fachsymposien), press releases and policy position papers, member consultation services, a newsletter, and advocacy events such as Parliamentary Evening events. These services collectively support the association's mission to represent pharmaceutical cannabinoid companies and ensure patient access to quality-assured medical cannabis in Germany.

Differentiator

Problem solved

Functional benefit

Products and services

• Fortbildungs-Webinare (Educational Webinars) Continuing education webinars for medical and pharmacy students and healthcare professionals covering medicinal cannabis topics.
• Fachsymposien (Professional Symposiums) Annual professional symposiums bringing together industry experts, policymakers, and healthcare professionals to discuss medical cannabis regulation, therapy developments, and supply structures.
• Press Releases and Position Papers Formal policy statements and position papers on medical cannabis legislation, statutory health insurance (GKV) reimbursement policy, telemedicine regulations, and supply chain issues, with recommendations to policymakers.
• Mitglieder-Service (Member Services) Member services providing regulatory and political updates, consultation on research partnerships, and evidence generation opportunities for member pharmaceutical cannabinoid companies.
• Parlamentarischer Abend (Parliamentary Evening Events) Annual networking events held at the Deutsche Parlamentarische Gesellschaft (German Parliamentary Society) to facilitate dialogue between politicians, industry representatives, and healthcare professionals on medical cannabis policy.
• Newsletter Monthly newsletter providing members and subscribers with updates on regulatory developments, political news, and events in the medical cannabis sector.

Quantifiable outcome

• BPC represents member companies serving an estimated 600,000 to 800,000 medical cannabis patients in Germany
• +2 more outcomes

Named customers15 records

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Seven partnerships are on record, tiered core and minor.

• Verband der Cannabis versorgenden Apotheken e.V. (VCA)coreStrategic or Co-development PartnerBPC and VCA have formed a strategic partnership including joint webinar series for medical and pharmacy students on medicinal cannabis topics. The organizations coordinate on policy positions regarding telemedicine, shipping regulations, and patient access to medical cannabis.
• Euromonitor InternationalminorStrategic or Co-development PartnerEuromonitor International provided market analysis at BPC's Parliamentary Evening 2025, presenting data on the German medical cannabis market valued at over 2 billion Euro with 600,000-800,000 patients.
• Deutsches Zentrum für Medizinalcannabis (DZMC)minorStrategic or Co-development PartnerDZMC founder Dr. Thomas Vaterrodt participated in BPC Parliamentary Evening 2025, providing insights on supply reality and challenges between approval, recourse, and patient access.
• Bund Deutscher Cannabis-Patienten e.V. (BDCan)coreStrategic or Co-development PartnerBDCan participates in coalition statements with BPC regarding medical cannabis policy, including joint opposition to proposed shipping bans and telemedicine restrictions.
• Arbeitsgemeinschaft Cannabis als Medizin e.V. (ACM)coreStrategic or Co-development PartnerACM is part of the coalition of medical cannabis associations working with BPC on policy positions and patient advocacy.
• Branchenverband Cannabiswirtschaft e.V. (BvCW)coreStrategic or Co-development PartnerBvCW participates in coalition statements with BPC and other associations on cannabis policy matters.
• Burkhard Blienert (Senior Advisor)coreOthersFormer Federal Drug Commissioner Burkhard Blienert joined BPC as Senior Advisor for political strategy consulting since November 1, 2025, bringing expertise in German drug and health policy.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Bundesverband der Pharmazeutischen Industrie (BPI): Leading German pharmaceutical industry association covering prescription and OTC medicines. Comparable as a major German pharma trade body with established lobbying infrastructure before BfArM, BMG and G-BA, against which BPC competes for policymaker attention on cannabis issues.
• Pro Generika e.V. German trade association for generics manufacturers. Comparable as a German pharma-sector industry association engaging with BMG and GKV on reimbursement policy, though not cannabis-specific; offers a template for how BPC could mature its policy-influence infrastructure.

Direct peers

• International Association for Cannabinoid Medicines (IACM): International scientific and medical society for cannabinoid-based therapies. Comparable to BPC as a membership-based organisation advocating for evidence-based medical cannabis policy, though operating at a global rather than national level.
• Branchenverband Cannabiswirtschaft (BvCW): German cannabis industry trade association covering the broader cannabis economy (cultivation, distribution, ancillary services). BPC and BvCW already coordinate on coalition statements, making them the closest functional peer focused on German cannabis policy representation.
• Verband der Cannabis versorgenden Apotheken (VCA): German association of cannabis-dispensing pharmacies. VCA is a BPC coalition partner running joint webinars, and represents the downstream pharmacy segment of the same medical cannabis value chain that BPC's producer/importer members supply.
• Bund Deutscher Cannabis-Patienten (BDCan): German association representing medical cannabis patients. BDCan is a BPC coalition partner with overlapping advocacy goals (telemedicine, shipping, reimbursement) and shares the same non-profit association structure.
• Arbeitsgemeinschaft Cannabis als Medizin (ACM): Germany-based medical-scientific association promoting cannabis as medicine. ACM works with BPC on policy and patient-access positions and shares the same regulatory advocacy remit focused on the MedCanG/CanG framework.

Regional players

• European Industrial Hemp Association (EIHA): European trade association representing the industrial hemp value chain. Comparable as a sector-specific industry association but covers broader hemp (fibre, food, supplements) rather than BPC's pharmaceutical-cannabinoid focus, and operates at EU rather than German level.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/bpc_ev
• LinkedInlinkedin.com/company/bundesverband-pharmazeutischer-cannabnoidunternehmen-e-v

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bundesverband pharmazeutischer Cannabinoidunternehmen